Get the Stockscreener App
3.65
1.39%
+0.05
Genelux Corp stock is currently priced at $3.65, with a 24-hour trading volume of 52,505.
It has seen a +1.39% increased in the last 24 hours and a +0.97% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.59 pivot point. If it approaches the $3.67 resistance level, significant changes may occur.
Previous Close:
$3.60
Open:
$3.62
24h Volume:
52,505
Market Cap:
$98.54M
Revenue:
-
Net Income/Loss:
$-28.30M
P/E Ratio:
-5.3811
EPS:
-0.6783
Net Cash Flow:
$-21.30M
1W Performance:
-4.70%
1M Performance:
+0.97%
6M Performance:
-69.25%
1Y Performance:
-85.22%
1D Range:
$3.47
$3.73
52W Range:
$3.06
$40.98
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
858 483 0024
Address
2625 Townsgate Road, Suite 230, Westlake Village
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Apollon Wealth Management LLC Buys New Shares in Genelux Co. (NASDAQ:GNLX) - Defense World
Defense World
Genelux Corp insider sells over $130k in company stock - Investing.com Australia
Investing.com Australia
Genelux Corp insider sells over $130k in company stock - Investing.com India
Investing.com India
Genelux's (GNLX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
MarketBeat
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates - Yahoo Finance
Yahoo Finance
Aladar Szalay Sells 6,025 Shares of Genelux Co. (NASDAQ:GNLX) Stock - MarketBeat
MarketBeat
Genelux Corp Stock (GNLX) Financials Data
Genelux Corp (GNLX) Net Income 2024
GNLX net income (TTM) was -$28.30 million for the quarter ending December 31, 2023, a -443.44% decrease year-over-year.
Genelux Corp (GNLX) Cash Flow 2024
GNLX recorded a free cash flow (TTM) of -$21.30 million for the quarter ending December 31, 2023, a -488.40% decrease year-over-year.
Genelux Corp (GNLX) Earnings per Share 2024
GNLX earnings per share (TTM) was -$1.21 for the quarter ending December 31, 2023, a -567.77% decline year-over-year.
Genelux Corp Stock (GNLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Szalay Aladar | 10% Owner |
May 14 '24 |
Sale |
3.58 |
15,426 |
55,274 |
1,156,915 |
| Szalay Aladar | 10% Owner |
May 13 '24 |
Sale |
3.62 |
3,446 |
12,478 |
1,172,341 |
| Szalay Aladar | 10% Owner |
May 08 '24 |
Sale |
3.82 |
13,919 |
53,189 |
1,175,787 |
| Szalay Aladar | 10% Owner |
May 07 '24 |
Sale |
3.67 |
6,025 |
22,111 |
1,189,706 |
| Szalay Aladar | 10% Owner |
May 01 '24 |
Sale |
3.30 |
33,061 |
109,161 |
1,195,731 |
| Szalay Aladar | 10% Owner |
Apr 30 '24 |
Sale |
3.12 |
20,535 |
63,981 |
1,228,792 |
| Szalay Aladar | 10% Owner |
Apr 29 '24 |
Sale |
3.25 |
6,403 |
20,792 |
1,249,327 |
| Szalay Aladar | 10% Owner |
Apr 24 '24 |
Sale |
3.50 |
8,064 |
28,251 |
1,255,730 |
| Szalay Aladar | 10% Owner |
Apr 23 '24 |
Sale |
3.49 |
22,000 |
76,800 |
1,263,794 |
| Szalay Aladar | 10% Owner |
Apr 22 '24 |
Sale |
3.53 |
14,331 |
50,597 |
1,285,794 |
About Genelux Corp
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
0.77%
1.20%
Cap:
|
Volume (24h):